ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite’s low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes.
In December of 2023, ASCO and ConcertAI announced the acquisition of CancerLinQ and ongoing network operations as a ConcertAI initiative. Over the last year and a half, ConcertAI has advanced the SmartLinQ application for QOPI® applications as well as advanced notifications of potentially beneficial diagnostics and newly approved therapeutics for a provider’s patients. SmartLinQ works directly within the workflows of Epic and other EMRs. ASCO Guidelines will be augmenting the SmartLinQ solution by June 15th as part of the company’s effort to assure that all network practices have that informational resource.
On May 30th, ConcertAI announced its oncology Precision Suite™ of generative and agentic AI solutions for advancing analytics and inferences, and for clinical trial design and optimization. The ASCO Guidelines will be available within these solutions by June 30th for assessment of Guideline-concordant care across the widest array of settings, and to inform the design of clinical trial controls according to published clinical recommendations.
Also Read: Cellares with Mitsui to Launch Japan’s First IDMO Factory
“Through CancerLinQ, ConcertAI has an almost decade-long history of collaborating with ASCO,” said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. “This license of ASCO Guidelines represents a new opportunity to harness the latest generative and agentic AI technologies to promote high-quality cancer care, evidence generation, and advanced care insights.”
The CancerLinQ SmartLinQ deployment of these guidelines will be available to demonstrate at the 2025 ASCO Annual Meeting in Chicago.
SOURCE: BusinessWire
